The global Phacoemulsification System Market is witnessing steady growth due to increasing prevalence of cataract, rising geriatric population, and technological advancements in ophthalmic surgeries. Valued at USD 3.7 billion in 2023, the market is projected to reach USD 3.9 billion in 2024, reflecting a 5.4% year-over-year growth. Surge in outpatient ophthalmic procedures and adoption of minimally invasive cataract surgeries are driving demand across hospitals and specialized eye care centers worldwide.

Historical Market Trends (2014–2023)

Over the last decade, the Phacoemulsification System Market has demonstrated consistent growth. In 2014, global revenue stood at USD 1.9 billion, which increased to USD 2.4 billion in 2017, representing a 7.8% CAGR. By 2019, revenue reached USD 3.0 billion, primarily due to adoption of advanced phacoemulsification machines and increasing cataract surgeries. Even during the COVID-19 pandemic, the market grew 4.2% in 2020, reflecting continued demand for essential ophthalmic procedures.

Year-over-Year Market Dynamics

Recent year-over-year data indicates steady expansion:

• 2020–2021: USD 3.1 billion to USD 3.2 billion, 3.2% growth

• 2021–2022: USD 3.2 billion to USD 3.5 billion, 9.4% increase

• 2022–2023: USD 3.5 billion to USD 3.7 billion, 5.7% growth

• 2023–2024 (forecasted): USD 3.7 billion to USD 3.9 billion, 5.4% growth

A 2023 survey across 15 countries reported that over 65% of ophthalmic surgeons prefer advanced phacoemulsification systems to reduce surgical time and improve patient outcomes.

Technological Advancements Driving Growth

Phacoemulsification machines have integrated features such as torsional ultrasound, fluidics control, and real-time feedback monitoring. The adoption of femtosecond laser-assisted phaco systems has grown from 12% of installations in 2018 to 28% in 2023. Leading manufacturers invested over USD 250 million in R&D between 2020–2024 to improve energy efficiency, reduce heat generation, and enhance surgical precision.

Regional Insights

• North America leads with 34% of global revenue in 2024, with the U.S. alone generating USD 1.3 billion in annual sales.

• Europe holds 27% of the market, with Germany, France, and the U.K. accounting for over USD 1.0 billion in 2023.

• Asia-Pacific is the fastest-growing region at 9.1% CAGR from 2024–2032, with India, China, and Japan driving demand. India reported 1.2 million cataract surgeries in 2023, contributing USD 420 million to regional market revenue.

• Latin America and Middle East & Africa collectively account for 12% of global revenue, with Brazil and UAE as key contributors.

Market Segmentation: Hospital vs Ambulatory Surgery Centers

Hospitals dominate the Phacoemulsification System Market, representing 68% of global revenue, while ambulatory surgery centers account for 32%. Between 2018–2023, the number of outpatient ophthalmic facilities increased by 18%, driving phaco system adoption. Hospitals’ investment in premium phaco machines reached USD 1.9 billion in 2023, an 11% rise from 2022.

Distribution Channels and Procurement Trends

OEMs contribute 57% of total market revenue, while distributors hold 28%, and e-commerce accounts for 15%. Direct procurement through OEMs ensures long-term service and software updates, which 63% of hospitals prioritize. Seasonal procurement peaks during Q2–Q3, coinciding with budget allocations for medical equipment in hospitals and private clinics.

Competitive Landscape

The market is moderately consolidated. Leading manufacturers hold 49% of global revenue, while regional players account for 51%. Annual revenues of top companies range between USD 2–10 billion, with phacoemulsification systems contributing 4–7% of total revenue. Global production volumes exceeded 215,000 units in 2023, up from 160,000 units in 2017, reflecting a 34% growth over six years.

Future Outlook (2024–2032)

The Phacoemulsification System Market is projected to grow from USD 3.9 billion in 2024 to USD 6.8 billion by 2032, at a CAGR of 7.2%. Hospitals will continue to drive majority adoption, while ambulatory surgery centers are expected to increase their share to 38% by 2030. Asia-Pacific is projected to generate over USD 1.5 billion in incremental revenue during the forecast period. Technological advancements and rising geriatric population will sustain market momentum.

Data-Driven Conclusion

The Phacoemulsification System Market has grown from USD 1.9 billion in 2014 to USD 3.7 billion in 2023, reflecting strong demand for efficient cataract surgery solutions. Annual production exceeded 215,000 units in 2023, with North America and Europe maintaining dominant revenue shares. Asia-Pacific’s rapid adoption and continuous technological innovation position the market to reach USD 6.8 billion by 2032, confirming long-term growth potential in global ophthalmic surgical equipment.

Read Full Research Study: https://marketintelo.com/report/phacoemulsification-system-market